GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Apures Co Ltd (XKRX:149300) » Definitions » Debt-to-EBITDA

Apures Co (XKRX:149300) Debt-to-EBITDA : -1.84 (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Apures Co Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Apures Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₩3,610.4 Mil. Apures Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₩2,632.0 Mil. Apures Co's annualized EBITDA for the quarter that ended in Dec. 2023 was ₩-3,401.7 Mil. Apures Co's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -1.84.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Apures Co's Debt-to-EBITDA or its related term are showing as below:

XKRX:149300' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -14.56   Med: -2.4   Max: -1.21
Current: -1.84

During the past 10 years, the highest Debt-to-EBITDA Ratio of Apures Co was -1.21. The lowest was -14.56. And the median was -2.40.

XKRX:149300's Debt-to-EBITDA is ranked worse than
100% of 101 companies
in the Medical Diagnostics & Research industry
Industry Median: 1.76 vs XKRX:149300: -1.84

Apures Co Debt-to-EBITDA Historical Data

The historical data trend for Apures Co's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apures Co Debt-to-EBITDA Chart

Apures Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.21 -1.30 -12.52 -2.47 -1.84

Apures Co Semi-Annual Data
Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.21 -1.30 -12.52 -2.47 -1.84

Competitive Comparison of Apures Co's Debt-to-EBITDA

For the Diagnostics & Research subindustry, Apures Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Apures Co's Debt-to-EBITDA Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Apures Co's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Apures Co's Debt-to-EBITDA falls into.



Apures Co Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Apures Co's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(3610.362 + 2632.019) / -3401.663
=-1.84

Apures Co's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(3610.362 + 2632.019) / -3401.663
=-1.84

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is one times the quarterly (Dec. 2023) EBITDA data.


Apures Co  (XKRX:149300) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Apures Co Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Apures Co's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Apures Co (XKRX:149300) Business Description

Traded in Other Exchanges
N/A
Address
44, Hansan-gil, Cheongbuk-eup, Gyeonggi-do, Pyeongtaek-si, KOR, 17792
Apures Co Ltd is a South Korea based company engaged in the development of transgenic animals to support bio heterogeneous long-term commercialization and new drug efficacy research. It has focused its research capabilities on developing transgenic mini pigs based on gene editing technology and somatic cell nuclear transfer technology.

Apures Co (XKRX:149300) Headlines

No Headlines